Cancer Research UK and AstraZeneca have announced that they are opening a new centre in Cambridge dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.

By combining the experience and expertise of both organisations in cancer biology and functional genomics, including CRISPR technologies, it’s hoped that this state-of-the-art facility will help deliver new treatments to patients much faster.

“We’re delighted to collaborate with AstraZeneca on this exciting new initiative, which will give leading Cancer Research UK scientists and our alliance partners access to the latest in CRISPR technology,” said Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation.

“As we move into an era of personalised medicine, we’ve reached a turning point in our ability to harness powerful technologies in the pursuit of targeted cancer therapies. We hope that this will translate into urgently needed new therapies for patients with hard to treat cancers, such as lung, pancreatic, oesophageal and brain tumours.”

Back to e-newsletter